# Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes

> **NCT07121569** · PHASE4 · COMPLETED · sponsor: **Universitas Sebelas Maret** · enrollment: 52 (actual)

## Conditions studied

- Ischemic Stroke, Acute

## Interventions

- **DRUG:** Oral lumbrokinase DLBS1033
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07121569
- **Lead sponsor:** Universitas Sebelas Maret
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-06
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-03-13
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121569, "Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07121569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*